PCYN (Procyon) Debt-to-Equity: 0.14 (As of Jun. 2024)


PCYN Procyon Corp PCYN
48 GF Score
Price $0.20
View Full Analysis

What is Procyon Debt-to-Equity?

Procyon PCYN 48 Debt-to-Equity is 0.14 as of Jun. 2024. GuruFocus rates PCYN with a GF Score™ of 48/100.

Procyon's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.18 Mil. Procyon's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.14 Mil. Procyon's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $2.29 Mil. Procyon's debt to equity for the quarter that ended in Jun. 2024 was 0.14.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Procyon's Debt-to-Equity or its related term are showing as below:

PCYN's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.27
* Ranked among companies with meaningful Debt-to-Equity only.

Procyon  (OTCPK:PCYN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Procyon Debt-to-Equity Related Terms

Procyon Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Procyon's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Procyon Debt-to-Equity Chart

Procyon Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.28 0.25 0.19 0.14

Procyon Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.17 0.17 0.16 0.14

PCYN vs KAYS, YCBD, CBDY: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Procyon's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Procyon Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procyon's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Procyon's Debt-to-Equity falls into.


PCYN
48GF Score
Procyon Corp PCYN
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Procyon Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Procyon's Debt to Equity Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.181 + 0.139) / 2.287
=0.14

Procyon's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.181 + 0.139) / 2.287
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.14 mean?
Procyon (PCYN) has a Debt-to-Equity of 0.14 as of Jun. 2024. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Procyon and its competitors.
Is Procyon's Debt-to-Equity too high?
Procyon's current Debt-to-Equity is 0.14. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Procyon's value of 0.14 is 48.1% below this industry median. Overall, Procyon has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Procyon's Debt-to-Equity compare to KAYS and YCBD?
Procyon's Debt-to-Equity of 0.14 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.27. Procyon's value of 0.14 is 48.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Procyon's current Debt-to-Equity of 0.14 is 48.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Procyon and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procyon's current Debt-to-Equity is 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procyon stock overvalued right now?
Procyon (PCYN) has a current Debt-to-Equity of 0.14. The current Debt-to-Equity is 0.14 and 48.1% below the Drug Manufacturers industry median of 0.27. Procyon's overall GF Score™ is 48/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Procyon (PCYN), the current Debt-to-Equity is 0.14 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Procyon Business Description

Address 164 Douglas Road East, Oldsmar, FL, USA, 34677
Procyon Corp is a United-based company, through its subsidiary, it is engaged in developing and marketing proprietary medical products used to treat pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems. Its wound care products are sold through distributors to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, and physicians and other healthcare practitioners. The firm's product lines are AMERX, AMERIGEL, and HELIX3 Bioactive Collagen. The skin and wound care products are marketed under the trademark AMERIGEL which contains the proprietary ingredient OAKIN which promotes wound healing and healthy skin. The corporation markets its products in the United States.
48GF Score

Get the complete analysis for PCYN

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price